Idiopathic membranous nephropathy a glomerular disease usually of abrupt onset and associated with the nephrotic syndrome. Membranous nephropathy occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria).
R&D in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic membranous nephropathy treatment market. In July 2019, the study, ‘Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy’ stated that rituximab as effective as cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months.
Most leading manufactures in the idiopathic membranous nephropathy treatment market are involved in the production of medicines for treatment of idiopathic membranous nephropathy. Recent clinical trials have shown that medicines which act on the musculoskeletal system can provide a rapid relief of symptoms in patients with mild to moderate nephrolithiasis. Advancing research and developments in this area is anticipated to support the worldwide, large-scale, commercialize idiopathic membranous nephropathy treatment market. In November 2019, Novartis Pharmaceuticals imitated a randomized study evaluating the efficacy and safety of LNP023 compared with rituximab in subjects with membranous nephropathy who are at high risk of disease progression defined on the basis of antibody anti-PLA2R titre and proteinuria.
The idiopathic membranous nephropathy treatment market in Asia Pacific is also driven by R&D of new drugs. In June 2018, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, initiated a random trial to assess the urine protein remission rate of tacrolimus monotherapy for idiopathic membranous nephropathy. In December 2020, ValenzaBio, a privately-held biopharmaceutical company developing therapies for autoimmune and inflammatory diseases, initiated a Phase 1b/2a, open-label, sequential-cohort, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with primary membranous nephropathy. VB119 is a humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) that can be administered as intravenous infusion at multiple timepoints during the study.
In November 2020, Hoffmann-La Roche, a major player in the idiopathic membranous nephropathy treatment market, initiated a study to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy.
No comments:
Post a Comment